Urinary galectin-3 binding protein (G3BP) as a biomarker for disease activity and renal pathology characteristics in lupus nephritis

There is an urgent need to identify novel biomarkers of LN to reflect renal histological changes. This study aims to investigate urinary G3BP levels in LN patients and their association with renal disease activity both clinically and pathologically. This is a cross-sectional study. A total of 119 lu...

Full description

Saved in:
Bibliographic Details
Published inArthritis research & therapy Vol. 24; no. 1; pp. 77 - 10
Main Authors Ding, Huihua, Shen, Yiwei, Lin, Cheng, Qin, Ling, He, Shijun, Dai, Min, Okitsu, Shinji L., DeMartino, Julie A., Guo, Qiang, Shen, Nan
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 28.03.2022
BioMed Central
BMC
Subjects
Activity index
Antigens, Neoplasm - urine
Arthritis
Biomarker
Biomarkers
Biomarkers - metabolism
Biomarkers, Tumor - urine
Biopsy
Chronic kidney failure
Comparative analysis
Correlation analysis
Creatinine
Cross-Sectional Studies
Development and progression
Diagnosis
Galectin 3
Galectin-3 binding protein
Health aspects
Humans
Kidney - pathology
Kidney diseases
Lupus
Lupus nephritis
Lupus Nephritis - pathology
Nephritis
Pathology
Patients
Protein binding
Proteins
Renal biopsy
Rheumatology
Systemic lupus erythematosus
Urine
Variance analysis
China
Minneapolis Minnesota
United States > US
Biomarker
Renal biopsy
Systemic lupus erythematosus
Lupus nephritis
Activity index
Galectin-3 binding protein
Online AccessGet full text

Cover

Abstract There is an urgent need to identify novel biomarkers of LN to reflect renal histological changes. This study aims to investigate urinary G3BP levels in LN patients and their association with renal disease activity both clinically and pathologically. This is a cross-sectional study. A total of 119 lupus nephritis patients were recruited. Thirty patients with chronic kidney diseases (CKD) and 27 healthy volunteers were also recruited as controls. Urinary G3BP was tested by ELISA. Renal histopathology was reviewed by an experienced renal pathologist. Other clinical variables were collected through chart review. The levels of uG3BP were significantly increased in active LN patients compared to those in inactive LN (p<0.001), CKD patients (p=0.01), and healthy controls (p<0.001). ROC analysis indicated a good discrimination ability of uG3BP to differentiate active LN from CKD patients (AUC=0.7), inactive LN (AUC=0.76), or healthy controls (AUC=0.87). uG3BP was positively correlated with SLEDAI (ρ=0.352, p<0.001), rSLEDAI (ρ=0.302, p<0.001), and SLICC RAS (ρ=0.465, p<0.001), indicating a role as a biomarker of disease activity. It also correlated with clinical parameters, including 24-h urine protein, ESR, and serum C3 levels. In patients with 24-h urine protein > 3.0 g/24h, uG3BP levels were higher in proliferative LN than in membranous LN (p=0.04). They could discriminate the two pathogenic types of LN (AUC=0.72), and they also positively correlated with AI (ρ=0.389, p=0.008) and scores of hyaline deposits (ρ=0.418, p=0.006). While in patients with 24-h urine protein ≤ 3.0 g/24h, uG3BP levels were not significantly different between proliferative and membranous LN, and there was no apparent relationship between uG3BP levels with AI or with scores of hyaline deposits, but they correlated positively with scores of cellular/fibrocellular crescents (ρ=0.328, p=0.04). uG3BP is a non-invasive biomarker for clinically and histologically reflecting disease activity. It is associated with active histological changes and can be used as a surrogate biomarker when the renal biopsy is impractical.
AbstractList Abstract Objective There is an urgent need to identify novel biomarkers of LN to reflect renal histological changes. This study aims to investigate urinary G3BP levels in LN patients and their association with renal disease activity both clinically and pathologically. Methods This is a cross-sectional study. A total of 119 lupus nephritis patients were recruited. Thirty patients with chronic kidney diseases (CKD) and 27 healthy volunteers were also recruited as controls. Urinary G3BP was tested by ELISA. Renal histopathology was reviewed by an experienced renal pathologist. Other clinical variables were collected through chart review. Results The levels of uG3BP were significantly increased in active LN patients compared to those in inactive LN (p<0.001), CKD patients (p=0.01), and healthy controls (p<0.001). ROC analysis indicated a good discrimination ability of uG3BP to differentiate active LN from CKD patients (AUC=0.7), inactive LN (AUC=0.76), or healthy controls (AUC=0.87). uG3BP was positively correlated with SLEDAI (ρ=0.352, p<0.001), rSLEDAI (ρ=0.302, p<0.001), and SLICC RAS (ρ=0.465, p<0.001), indicating a role as a biomarker of disease activity. It also correlated with clinical parameters, including 24-h urine protein, ESR, and serum C3 levels. In patients with 24-h urine protein > 3.0 g/24h, uG3BP levels were higher in proliferative LN than in membranous LN (p=0.04). They could discriminate the two pathogenic types of LN (AUC=0.72), and they also positively correlated with AI (ρ=0.389, p=0.008) and scores of hyaline deposits (ρ=0.418, p=0.006). While in patients with 24-h urine protein ≤ 3.0 g/24h, uG3BP levels were not significantly different between proliferative and membranous LN, and there was no apparent relationship between uG3BP levels with AI or with scores of hyaline deposits, but they correlated positively with scores of cellular/fibrocellular crescents (ρ=0.328, p=0.04). Conclusion uG3BP is a non-invasive biomarker for clinically and histologically reflecting disease activity. It is associated with active histological changes and can be used as a surrogate biomarker when the renal biopsy is impractical.
There is an urgent need to identify novel biomarkers of LN to reflect renal histological changes. This study aims to investigate urinary G3BP levels in LN patients and their association with renal disease activity both clinically and pathologically.OBJECTIVEThere is an urgent need to identify novel biomarkers of LN to reflect renal histological changes. This study aims to investigate urinary G3BP levels in LN patients and their association with renal disease activity both clinically and pathologically.This is a cross-sectional study. A total of 119 lupus nephritis patients were recruited. Thirty patients with chronic kidney diseases (CKD) and 27 healthy volunteers were also recruited as controls. Urinary G3BP was tested by ELISA. Renal histopathology was reviewed by an experienced renal pathologist. Other clinical variables were collected through chart review.METHODSThis is a cross-sectional study. A total of 119 lupus nephritis patients were recruited. Thirty patients with chronic kidney diseases (CKD) and 27 healthy volunteers were also recruited as controls. Urinary G3BP was tested by ELISA. Renal histopathology was reviewed by an experienced renal pathologist. Other clinical variables were collected through chart review.The levels of uG3BP were significantly increased in active LN patients compared to those in inactive LN (p<0.001), CKD patients (p=0.01), and healthy controls (p<0.001). ROC analysis indicated a good discrimination ability of uG3BP to differentiate active LN from CKD patients (AUC=0.7), inactive LN (AUC=0.76), or healthy controls (AUC=0.87). uG3BP was positively correlated with SLEDAI (ρ=0.352, p<0.001), rSLEDAI (ρ=0.302, p<0.001), and SLICC RAS (ρ=0.465, p<0.001), indicating a role as a biomarker of disease activity. It also correlated with clinical parameters, including 24-h urine protein, ESR, and serum C3 levels. In patients with 24-h urine protein > 3.0 g/24h, uG3BP levels were higher in proliferative LN than in membranous LN (p=0.04). They could discriminate the two pathogenic types of LN (AUC=0.72), and they also positively correlated with AI (ρ=0.389, p=0.008) and scores of hyaline deposits (ρ=0.418, p=0.006). While in patients with 24-h urine protein ≤ 3.0 g/24h, uG3BP levels were not significantly different between proliferative and membranous LN, and there was no apparent relationship between uG3BP levels with AI or with scores of hyaline deposits, but they correlated positively with scores of cellular/fibrocellular crescents (ρ=0.328, p=0.04).RESULTSThe levels of uG3BP were significantly increased in active LN patients compared to those in inactive LN (p<0.001), CKD patients (p=0.01), and healthy controls (p<0.001). ROC analysis indicated a good discrimination ability of uG3BP to differentiate active LN from CKD patients (AUC=0.7), inactive LN (AUC=0.76), or healthy controls (AUC=0.87). uG3BP was positively correlated with SLEDAI (ρ=0.352, p<0.001), rSLEDAI (ρ=0.302, p<0.001), and SLICC RAS (ρ=0.465, p<0.001), indicating a role as a biomarker of disease activity. It also correlated with clinical parameters, including 24-h urine protein, ESR, and serum C3 levels. In patients with 24-h urine protein > 3.0 g/24h, uG3BP levels were higher in proliferative LN than in membranous LN (p=0.04). They could discriminate the two pathogenic types of LN (AUC=0.72), and they also positively correlated with AI (ρ=0.389, p=0.008) and scores of hyaline deposits (ρ=0.418, p=0.006). While in patients with 24-h urine protein ≤ 3.0 g/24h, uG3BP levels were not significantly different between proliferative and membranous LN, and there was no apparent relationship between uG3BP levels with AI or with scores of hyaline deposits, but they correlated positively with scores of cellular/fibrocellular crescents (ρ=0.328, p=0.04).uG3BP is a non-invasive biomarker for clinically and histologically reflecting disease activity. It is associated with active histological changes and can be used as a surrogate biomarker when the renal biopsy is impractical.CONCLUSIONuG3BP is a non-invasive biomarker for clinically and histologically reflecting disease activity. It is associated with active histological changes and can be used as a surrogate biomarker when the renal biopsy is impractical.
Objective There is an urgent need to identify novel biomarkers of LN to reflect renal histological changes. This study aims to investigate urinary G3BP levels in LN patients and their association with renal disease activity both clinically and pathologically. Methods This is a cross-sectional study. A total of 119 lupus nephritis patients were recruited. Thirty patients with chronic kidney diseases (CKD) and 27 healthy volunteers were also recruited as controls. Urinary G3BP was tested by ELISA. Renal histopathology was reviewed by an experienced renal pathologist. Other clinical variables were collected through chart review. Results The levels of uG3BP were significantly increased in active LN patients compared to those in inactive LN (p<0.001), CKD patients (p=0.01), and healthy controls (p<0.001). ROC analysis indicated a good discrimination ability of uG3BP to differentiate active LN from CKD patients (AUC=0.7), inactive LN (AUC=0.76), or healthy controls (AUC=0.87). uG3BP was positively correlated with SLEDAI ([rho]=0.352, p<0.001), rSLEDAI ([rho]=0.302, p<0.001), and SLICC RAS ([rho]=0.465, p<0.001), indicating a role as a biomarker of disease activity. It also correlated with clinical parameters, including 24-h urine protein, ESR, and serum C3 levels. In patients with 24-h urine protein > 3.0 g/24h, uG3BP levels were higher in proliferative LN than in membranous LN (p=0.04). They could discriminate the two pathogenic types of LN (AUC=0.72), and they also positively correlated with AI ([rho]=0.389, p=0.008) and scores of hyaline deposits ([rho]=0.418, p=0.006). While in patients with 24-h urine protein [less than or equai to] 3.0 g/24h, uG3BP levels were not significantly different between proliferative and membranous LN, and there was no apparent relationship between uG3BP levels with AI or with scores of hyaline deposits, but they correlated positively with scores of cellular/fibrocellular crescents ([rho]=0.328, p=0.04). Conclusion uG3BP is a non-invasive biomarker for clinically and histologically reflecting disease activity. It is associated with active histological changes and can be used as a surrogate biomarker when the renal biopsy is impractical. Keywords: Systemic lupus erythematosus, Lupus nephritis, Galectin-3 binding protein, Biomarker, Renal biopsy, Activity index
There is an urgent need to identify novel biomarkers of LN to reflect renal histological changes. This study aims to investigate urinary G3BP levels in LN patients and their association with renal disease activity both clinically and pathologically. This is a cross-sectional study. A total of 119 lupus nephritis patients were recruited. Thirty patients with chronic kidney diseases (CKD) and 27 healthy volunteers were also recruited as controls. Urinary G3BP was tested by ELISA. Renal histopathology was reviewed by an experienced renal pathologist. Other clinical variables were collected through chart review. The levels of uG3BP were significantly increased in active LN patients compared to those in inactive LN (p<0.001), CKD patients (p=0.01), and healthy controls (p<0.001). ROC analysis indicated a good discrimination ability of uG3BP to differentiate active LN from CKD patients (AUC=0.7), inactive LN (AUC=0.76), or healthy controls (AUC=0.87). uG3BP was positively correlated with SLEDAI ([rho]=0.352, p<0.001), rSLEDAI ([rho]=0.302, p<0.001), and SLICC RAS ([rho]=0.465, p<0.001), indicating a role as a biomarker of disease activity. It also correlated with clinical parameters, including 24-h urine protein, ESR, and serum C3 levels. In patients with 24-h urine protein > 3.0 g/24h, uG3BP levels were higher in proliferative LN than in membranous LN (p=0.04). They could discriminate the two pathogenic types of LN (AUC=0.72), and they also positively correlated with AI ([rho]=0.389, p=0.008) and scores of hyaline deposits ([rho]=0.418, p=0.006). While in patients with 24-h urine protein [less than or equai to] 3.0 g/24h, uG3BP levels were not significantly different between proliferative and membranous LN, and there was no apparent relationship between uG3BP levels with AI or with scores of hyaline deposits, but they correlated positively with scores of cellular/fibrocellular crescents ([rho]=0.328, p=0.04). uG3BP is a non-invasive biomarker for clinically and histologically reflecting disease activity. It is associated with active histological changes and can be used as a surrogate biomarker when the renal biopsy is impractical.
There is an urgent need to identify novel biomarkers of LN to reflect renal histological changes. This study aims to investigate urinary G3BP levels in LN patients and their association with renal disease activity both clinically and pathologically. This is a cross-sectional study. A total of 119 lupus nephritis patients were recruited. Thirty patients with chronic kidney diseases (CKD) and 27 healthy volunteers were also recruited as controls. Urinary G3BP was tested by ELISA. Renal histopathology was reviewed by an experienced renal pathologist. Other clinical variables were collected through chart review. The levels of uG3BP were significantly increased in active LN patients compared to those in inactive LN (p<0.001), CKD patients (p=0.01), and healthy controls (p<0.001). ROC analysis indicated a good discrimination ability of uG3BP to differentiate active LN from CKD patients (AUC=0.7), inactive LN (AUC=0.76), or healthy controls (AUC=0.87). uG3BP was positively correlated with SLEDAI (ρ=0.352, p<0.001), rSLEDAI (ρ=0.302, p<0.001), and SLICC RAS (ρ=0.465, p<0.001), indicating a role as a biomarker of disease activity. It also correlated with clinical parameters, including 24-h urine protein, ESR, and serum C3 levels. In patients with 24-h urine protein > 3.0 g/24h, uG3BP levels were higher in proliferative LN than in membranous LN (p=0.04). They could discriminate the two pathogenic types of LN (AUC=0.72), and they also positively correlated with AI (ρ=0.389, p=0.008) and scores of hyaline deposits (ρ=0.418, p=0.006). While in patients with 24-h urine protein ≤ 3.0 g/24h, uG3BP levels were not significantly different between proliferative and membranous LN, and there was no apparent relationship between uG3BP levels with AI or with scores of hyaline deposits, but they correlated positively with scores of cellular/fibrocellular crescents (ρ=0.328, p=0.04). uG3BP is a non-invasive biomarker for clinically and histologically reflecting disease activity. It is associated with active histological changes and can be used as a surrogate biomarker when the renal biopsy is impractical.
Objective There is an urgent need to identify novel biomarkers of LN to reflect renal histological changes. This study aims to investigate urinary G3BP levels in LN patients and their association with renal disease activity both clinically and pathologically. Methods This is a cross-sectional study. A total of 119 lupus nephritis patients were recruited. Thirty patients with chronic kidney diseases (CKD) and 27 healthy volunteers were also recruited as controls. Urinary G3BP was tested by ELISA. Renal histopathology was reviewed by an experienced renal pathologist. Other clinical variables were collected through chart review. Results The levels of uG3BP were significantly increased in active LN patients compared to those in inactive LN (p<0.001), CKD patients (p=0.01), and healthy controls (p<0.001). ROC analysis indicated a good discrimination ability of uG3BP to differentiate active LN from CKD patients (AUC=0.7), inactive LN (AUC=0.76), or healthy controls (AUC=0.87). uG3BP was positively correlated with SLEDAI (ρ=0.352, p<0.001), rSLEDAI (ρ=0.302, p<0.001), and SLICC RAS (ρ=0.465, p<0.001), indicating a role as a biomarker of disease activity. It also correlated with clinical parameters, including 24-h urine protein, ESR, and serum C3 levels. In patients with 24-h urine protein > 3.0 g/24h, uG3BP levels were higher in proliferative LN than in membranous LN (p=0.04). They could discriminate the two pathogenic types of LN (AUC=0.72), and they also positively correlated with AI (ρ=0.389, p=0.008) and scores of hyaline deposits (ρ=0.418, p=0.006). While in patients with 24-h urine protein ≤ 3.0 g/24h, uG3BP levels were not significantly different between proliferative and membranous LN, and there was no apparent relationship between uG3BP levels with AI or with scores of hyaline deposits, but they correlated positively with scores of cellular/fibrocellular crescents (ρ=0.328, p=0.04). Conclusion uG3BP is a non-invasive biomarker for clinically and histologically reflecting disease activity. It is associated with active histological changes and can be used as a surrogate biomarker when the renal biopsy is impractical.
ArticleNumber 77
Audience Academic
Author Okitsu, Shinji L.
Ding, Huihua
Dai, Min
Guo, Qiang
Shen, Yiwei
Shen, Nan
Lin, Cheng
DeMartino, Julie A.
Qin, Ling
He, Shijun
Author_xml – sequence: 1
  givenname: Huihua
  surname: Ding
  fullname: Ding, Huihua
– sequence: 2
  givenname: Yiwei
  surname: Shen
  fullname: Shen, Yiwei
– sequence: 3
  givenname: Cheng
  surname: Lin
  fullname: Lin, Cheng
– sequence: 4
  givenname: Ling
  surname: Qin
  fullname: Qin, Ling
– sequence: 5
  givenname: Shijun
  surname: He
  fullname: He, Shijun
– sequence: 6
  givenname: Min
  surname: Dai
  fullname: Dai, Min
– sequence: 7
  givenname: Shinji L.
  surname: Okitsu
  fullname: Okitsu, Shinji L.
– sequence: 8
  givenname: Julie A.
  surname: DeMartino
  fullname: DeMartino, Julie A.
– sequence: 9
  givenname: Qiang
  surname: Guo
  fullname: Guo, Qiang
– sequence: 10
  givenname: Nan
  surname: Shen
  fullname: Shen, Nan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35346341$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1DAURiNURB_wB1ggS2zKIiV-xI43SKWCUqkSLOjaunFuZjxk7GAnlWbPD8fTaaFTIRRZjuxzT3zj77g48MFjUbym1RmljXyfKK9UXVaM5aEkL8Wz4ogK1ZSSS3bw6P2wOE5pVWVSM_GiOOQ1F5ILelT8uonOQ9yQBQxoJ-dLTlrnO-cXZIxhQufJ6SX_-O0dgUQg74U1xB8YSR8i6VxCSEggV966aUPAdySih4GMMC3DEBYbYpcQM4DRpcnZRLJxmMc5EY_jMrrJpZfF8x6GhK_u55Pi5vOn7xdfyuuvl1cX59elrSWfSqU6KmkDQrYdaxXwVoBC3luwzHJZ5VnXGhmiajusdV0pRi2ndSt1L3rBT4qrnbcLsDJjdLmVjQngzN1CiAsDMZ9xQCMZoBRY8VZR0TNoUOmG9ZTWWtd1W2XXh51rnNs1dhb9FGHYk-7veLc0i3BrGi0ZozwLTu8FMfycMU1m7ZLFYQCPYU6GSSE0Vw2VGX37BF2FOea_vKVqqoXSmv2ltldpnO9D_q7dSs251E3OgVJNps7-QeWnw7WzOWC9y-t7BW8eN_qnw4cMZaDZATaGlCL2xroJJhe2fbvB0Mps42p2cTU5hOYurmZ7IexJ6YP9P0W_Aeyo7HQ
CitedBy_id crossref_primary_10_1177_09612033221145534
crossref_primary_10_3390_ijms232012607
crossref_primary_10_47360_1995_4484_2025_37_45
crossref_primary_10_3390_ijms241914526
crossref_primary_10_3390_ijms25168981
crossref_primary_10_3389_fphar_2024_1421657
Cites_doi 10.1177/0961203315580146
10.1016/S0021-9258(19)85233-X
10.1186/s12014-017-9146-0
10.1016/j.jaut.2016.06.006
10.1136/annrheumdis-2019-216312
10.1177/0961203319826695
10.1177/0961203308089441
10.1016/j.kint.2019.07.018
10.1136/lupus-2014-000026
10.1016/j.kint.2017.11.023
10.1093/rheumatology/33.12.1112
10.1186/ar3912
10.1021/jacs.5b04744
10.1002/art.23456
10.1038/s41572-019-0141-9
10.1007/BF00180543
10.1111/j.1365-2249.1994.tb06107.x
10.1177/0961203317747719
10.1053/j.ackd.2019.08.015
10.1016/j.kint.2018.05.021
10.1080/0886022X.2020.1726385
10.1093/rheumatology/kez528
10.1080/08820139.2019.1624769
10.1186/s13075-020-02209-9
10.1093/ndt/gfv296
10.4049/jimmunol.1500365
10.1073/pnas.0337679100
10.1093/rheumatology/ker101
10.1038/s41590-019-0398-x
10.1191/096120300678828749
10.1002/art.38065
ContentType Journal Article
Copyright 2022. The Author(s).
COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2022
Copyright_xml – notice: 2022. The Author(s).
– notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2022
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13075-022-02763-4
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic


MEDLINE
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1478-6362
EndPage 10
ExternalDocumentID oai_doaj_org_article_62ae64e03b714f2a8e7982f1159955b0
PMC8962213
A698636778
35346341
10_1186_s13075_022_02763_4
Genre Journal Article
GeographicLocations China
Minneapolis Minnesota
United States--US
GeographicLocations_xml – name: China
– name: Minneapolis Minnesota
– name: United States--US
GrantInformation_xml – fundername: ;
  grantid: 81771737
– fundername: ;
  grantid: SIMM2105KF-06
– fundername: ;
  grantid: 19411970100
– fundername: ;
  grantid: 82001709
GroupedDBID ---
.GJ
0R~
23N
2WC
4.4
5GY
5VS
6J9
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABUWG
ACGFS
ACJQM
ADBBV
ADUKV
AEGXH
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
E3Z
EBD
EBLON
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
HZ~
INH
INR
ITC
KQ8
M1P
O5R
O5S
O9-
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
U2A
UKHRP
WOQ
-5E
-5G
-A0
-BR
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
IAO
IHR
NPM
Z7U
PMFND
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c563t-77d1618a46bd2b7a3b4a7e3fcac2c360cac959e2ee7bde5950721c315b69f4f43
IEDL.DBID 7X7
ISSN 1478-6362
1478-6354
IngestDate Wed Aug 27 01:31:29 EDT 2025
Thu Aug 21 17:46:13 EDT 2025
Fri Jul 11 12:43:20 EDT 2025
Fri Jul 25 05:34:19 EDT 2025
Tue Jun 17 21:25:51 EDT 2025
Tue Jun 10 20:47:11 EDT 2025
Wed Feb 19 02:26:31 EST 2025
Thu Apr 24 23:05:32 EDT 2025
Tue Jul 01 04:00:59 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Biomarker
Renal biopsy
Systemic lupus erythematosus
Lupus nephritis
Activity index
Galectin-3 binding protein
Language English
License 2022. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c563t-77d1618a46bd2b7a3b4a7e3fcac2c360cac959e2ee7bde5950721c315b69f4f43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2651947992?pq-origsite=%requestingapplication%
PMID 35346341
PQID 2651947992
PQPubID 42876
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_62ae64e03b714f2a8e7982f1159955b0
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8962213
proquest_miscellaneous_2644937816
proquest_journals_2651947992
gale_infotracmisc_A698636778
gale_infotracacademiconefile_A698636778
pubmed_primary_35346341
crossref_citationtrail_10_1186_s13075_022_02763_4
crossref_primary_10_1186_s13075_022_02763_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-03-28
PublicationDateYYYYMMDD 2022-03-28
PublicationDate_xml – month: 03
  year: 2022
  text: 2022-03-28
  day: 28
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Arthritis research & therapy
PublicationTitleAlternate Arthritis Res Ther
PublicationYear 2022
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References G Moroni (2763_CR4) 2016; 74
DD Gladman (2763_CR10) 2002; 29
IM Bajema (2763_CR12) 2018; 93
2763_CR16
H-J Anders (2763_CR1) 2020; 6
I Parodis (2763_CR31) 2020; 59
A Malvar (2763_CR20) 2020; 97
K Egerer (2763_CR29) 2000; 9
GH Yao (2763_CR30) 2008; 17
K Vanarsa (2763_CR36) 2020; 79
CW Carson (2763_CR24) 1993; 20
AA Gasparin (2763_CR32) 2019; 28
RM De (2763_CR18) 2018; 94
I Parodis (2763_CR19) 2020; 59
YJ Lee (2763_CR8) 2007; 25
R-N Guo Liu (2763_CR33) 2020; 49
PE Spronk (2763_CR26) 1994; 97
SC Croca (2763_CR2) 2011; 50
CT Nielsen (2763_CR14) 2014; 1
BA Janssen (2763_CR25) 1994; 33
C Mrowka (2763_CR27) 1994; 72
T-W Lin (2763_CR6) 2015; 137
A Arazi (2763_CR17) 2019; 20
H Ding (2763_CR35) 2020; 22
MJV White (2763_CR5) 2015; 195
I Ayoub (2763_CR3) 2019; 26
J Tao (2763_CR21) 2020; 42
K Koths (2763_CR22) 1993; 268
CT Nielsen (2763_CR23) 2017; 14
S Singh (2763_CR34) 2012; 14
CT Nielsen (2763_CR15) 2015; 24
A Malvar (2763_CR37) 2017; 32
SS Ahn (2763_CR9) 2018; 27
M Petri (2763_CR11) 2008; 58
C Mrowka (2763_CR28) 1995; 43
A Marchetti (2763_CR7) 2002; 62
EC Baechler (2763_CR13) 2003; 100
References_xml – volume: 24
  start-page: 1150
  year: 2015
  ident: 2763_CR15
  publication-title: Lupus.
  doi: 10.1177/0961203315580146
– volume: 268
  start-page: 14245
  year: 1993
  ident: 2763_CR22
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(19)85233-X
– volume: 14
  start-page: 11
  year: 2017
  ident: 2763_CR23
  publication-title: Clin Proteomics
  doi: 10.1186/s12014-017-9146-0
– volume: 74
  start-page: 27
  year: 2016
  ident: 2763_CR4
  publication-title: J Autoimmun
  doi: 10.1016/j.jaut.2016.06.006
– volume: 79
  start-page: 1349
  year: 2020
  ident: 2763_CR36
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2019-216312
– volume: 28
  start-page: 265
  year: 2019
  ident: 2763_CR32
  publication-title: Lupus.
  doi: 10.1177/0961203319826695
– volume: 17
  start-page: 720
  year: 2008
  ident: 2763_CR30
  publication-title: Lupus.
  doi: 10.1177/0961203308089441
– volume: 97
  start-page: 156
  year: 2020
  ident: 2763_CR20
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2019.07.018
– volume: 1
  year: 2014
  ident: 2763_CR14
  publication-title: Lupus Sci Med
  doi: 10.1136/lupus-2014-000026
– volume: 93
  start-page: 789
  year: 2018
  ident: 2763_CR12
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2017.11.023
– volume: 20
  start-page: 809
  year: 1993
  ident: 2763_CR24
  publication-title: J Rheumatol
– volume: 33
  start-page: 1112
  year: 1994
  ident: 2763_CR25
  publication-title: Br J Rheumatol
  doi: 10.1093/rheumatology/33.12.1112
– volume: 14
  start-page: R164
  year: 2012
  ident: 2763_CR34
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar3912
– volume: 137
  start-page: 9685
  year: 2015
  ident: 2763_CR6
  publication-title: J Am Chem Soc
  doi: 10.1021/jacs.5b04744
– volume: 25
  start-page: S41
  year: 2007
  ident: 2763_CR8
  publication-title: Clin Exp Rheumatol
– volume: 58
  start-page: 1784
  year: 2008
  ident: 2763_CR11
  publication-title: Arthritis Rheum
  doi: 10.1002/art.23456
– volume: 6
  start-page: 7
  year: 2020
  ident: 2763_CR1
  publication-title: Nat Rev Dis Primers
  doi: 10.1038/s41572-019-0141-9
– volume: 72
  start-page: 762
  year: 1994
  ident: 2763_CR27
  publication-title: Clin Investig
  doi: 10.1007/BF00180543
– volume: 29
  start-page: 288
  year: 2002
  ident: 2763_CR10
  publication-title: J Rheumatol
– volume: 97
  start-page: 439
  year: 1994
  ident: 2763_CR26
  publication-title: Clin Exp Immunol
  doi: 10.1111/j.1365-2249.1994.tb06107.x
– volume: 62
  start-page: 2535
  year: 2002
  ident: 2763_CR7
  publication-title: Cancer Res
– volume: 27
  start-page: 771
  year: 2018
  ident: 2763_CR9
  publication-title: Lupus.
  doi: 10.1177/0961203317747719
– volume: 43
  start-page: 288
  year: 1995
  ident: 2763_CR28
  publication-title: Clin Nephrol
– volume: 26
  start-page: 360
  year: 2019
  ident: 2763_CR3
  publication-title: Adv Chronic Kidney Dis
  doi: 10.1053/j.ackd.2019.08.015
– volume: 94
  start-page: 788
  year: 2018
  ident: 2763_CR18
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2018.05.021
– volume: 42
  start-page: 166
  year: 2020
  ident: 2763_CR21
  publication-title: Ren Fail
  doi: 10.1080/0886022X.2020.1726385
– volume: 59
  start-page: 2237
  year: 2020
  ident: 2763_CR31
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kez528
– volume: 49
  start-page: 15
  year: 2020
  ident: 2763_CR33
  publication-title: Immunol Invest
  doi: 10.1080/08820139.2019.1624769
– volume: 22
  start-page: 1
  year: 2020
  ident: 2763_CR35
  publication-title: Arthritis Res Ther
  doi: 10.1186/s13075-020-02209-9
– volume: 32
  start-page: 1338
  year: 2017
  ident: 2763_CR37
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfv296
– volume: 195
  start-page: 1858
  year: 2015
  ident: 2763_CR5
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1500365
– volume: 100
  start-page: 2610
  year: 2003
  ident: 2763_CR13
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0337679100
– volume: 50
  start-page: 1424
  year: 2011
  ident: 2763_CR2
  publication-title: Rheumatology.
  doi: 10.1093/rheumatology/ker101
– volume: 20
  start-page: 902
  year: 2019
  ident: 2763_CR17
  publication-title: Nat Immunol
  doi: 10.1038/s41590-019-0398-x
– volume: 9
  start-page: 614
  year: 2000
  ident: 2763_CR29
  publication-title: Lupus.
  doi: 10.1191/096120300678828749
– ident: 2763_CR16
  doi: 10.1002/art.38065
– volume: 59
  start-page: 3424
  year: 2020
  ident: 2763_CR19
  publication-title: Revmatol.
SSID ssj0022924
Score 2.4127991
Snippet There is an urgent need to identify novel biomarkers of LN to reflect renal histological changes. This study aims to investigate urinary G3BP levels in LN...
Objective There is an urgent need to identify novel biomarkers of LN to reflect renal histological changes. This study aims to investigate urinary G3BP levels...
Abstract Objective There is an urgent need to identify novel biomarkers of LN to reflect renal histological changes. This study aims to investigate urinary...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 77
SubjectTerms Activity index
Antigens, Neoplasm - urine
Arthritis
Biomarker
Biomarkers
Biomarkers - metabolism
Biomarkers, Tumor - urine
Biopsy
Chronic kidney failure
Comparative analysis
Correlation analysis
Creatinine
Cross-Sectional Studies
Development and progression
Diagnosis
Galectin 3
Galectin-3 binding protein
Health aspects
Humans
Kidney - pathology
Kidney diseases
Lupus
Lupus nephritis
Lupus Nephritis - pathology
Nephritis
Pathology
Patients
Protein binding
Proteins
Renal biopsy
Rheumatology
Systemic lupus erythematosus
Urine
Variance analysis
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1baxUxEA7SB_FF1HpZrZKCoCJLz-aex1ZsS6Higwf6FpLsLB4o23Iu_8Af7kx2z-Esgr74tLBJNpeZJN9sMt8w9r5N0Glo2nqWwNcqCVNHoaAGcBIBhzGgyMH5-pu5nKurG32zF-qL7oQN9MDDwJ0YEcEomMlkG9WJ6MB6JzoEMt5rnYq1jnve1pgaTS2BZsXWRcaZkxWu1JY8kQWdWRpZq8k2VNj6_1yT9zal6YXJvR3o_Al7PEJHfjo0-Sl7AP0z9vB6PBw_ZL_my-Jcy6kCXMb6WvK0KF4rvNAxLHr-8UKeff_E44pHTp73dDlnyRG48vGkhpOjA8WT4LFv-RKoRopaXP6-8zyld-b4xdvN_WbFe0ClIHqk52x-_vXHl8t6DLJQZ23kGtF1S5z5UZnUimSjTCpakF2OWWRpZvj02oMAsKkF7TURqmXZ6GR8pzolX7CD_q6HV4wn0yqb2waNdad8Ss5C1-SWMIp2sm0q1mzHPOSRgZwCYdyGYok4EwY5BZRTKHIKqmKfd2XuB_6Nv-Y-I1HuchJ3dnmBGhVGjQr_0qiKfSA5BZrh2DwcgMFRATtJXFnh1HhnJBHvVexokhNnZp4mb1UpjCvDKgiDmFlZ70XFjnfJVJJuu_Vwt6E8SiFsdI2p2MtB83Zdkloqg9CjYnaik5M-T1P6xc_CG-68EaKRr__HIL1hj0SZTrIW7ogdrJcbeIvwbJ3elZn4GzIbNrM
  priority: 102
  providerName: Directory of Open Access Journals
Title Urinary galectin-3 binding protein (G3BP) as a biomarker for disease activity and renal pathology characteristics in lupus nephritis
URI https://www.ncbi.nlm.nih.gov/pubmed/35346341
https://www.proquest.com/docview/2651947992
https://www.proquest.com/docview/2644937816
https://pubmed.ncbi.nlm.nih.gov/PMC8962213
https://doaj.org/article/62ae64e03b714f2a8e7982f1159955b0
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9swFBZbC2MvY_d564oGg20M01iSdXkayWhXBi1lLJA3YcnHW6A4WS7_YD9858hOWjPoiwOWHFs6F326nO8w9r4O0JRQ1PkogMtVEDqvhIIcwEoEHFqDogDni0t9PlXfZ-WsX3Bb98cqdz4xOep6EWmN_ERoxBrKOCe-LP_klDWKdlf7FBr32SFRl5FWm9nNhEu4LqmtwpkSDqxqFzRj9ckafbeh2GRBu5ha5mowMCX-_v-99K1haniE8taYdPaYPerBJB930n_C7kH7lD246LfLn7G_01UKt-X0AnRsbS55mKc4Fp4IGuYt__hNTq4-8WrNK06x-HRcZ8URyvJ-74ZT6ANlmOBVW_MV0Bspj3Faj-dxSPjM8R-vt8vtmreAakKESc_Z9Oz059fzvE-7kMdSyw3i7ZpY9CulQy2CqWRQlQHZxCqKKPUIf7GrQQCYUEPpSqJYi7Iog3aNapR8wQ7aRQuvGA-6VibWBU7frXIhWANNEWtCLaWVdZGxYtfnPvac5JQa49qnuYnVvpOTRzn5JCevMvZ5_8yyY-S4s_aERLmvSWza6cZi9cv3xum1qEArGMlgCtWIyoJxVjQIlp0ryzDK2AeSkyebx8_DDuhCF7CRxJ7lx9pZLYmKL2NHg5poq3FYvFMl3_uKtb_R7Iy92xfTk3T-rYXFluoohUDSFjpjLzvN2zdJllJpBCMZMwOdHLR5WNLOfycmceu0EIV8ffdnvWEPRTIUmQt7xA42qy28RSi2CcfJ3o7Z4eT08urHcVrQwOtUjP8B6gw0ow
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4k2ggJFAgFDUjV-JDwi1QNnSbsWhlfZm4mQCK1XZZR9C3Pk9_EZmnGTbCKm3niLFzsOZ8cw3secbxl6UHioNSRkPPNhYeWHiXCiIATKJgMMYUJTgPDoywxP1ZazHG-xvlwtD2yo7mxgMdTkt6B_5tjCINVRqrXg_-xlT1ShaXe1KaDRqcQC_f2HItni3_xHl-1KIvU_HH4ZxW1UgLrSRS4STJZHE58r4Uvg0l17lKciqyAtRSDPAo9UWBEDqS9BWE4NYIRPtja1UpSTe9wq7io53QMFeOj4L8IRtiugqjMzQkasuSScz2wv0FSnlQgtaNTUyVj1HGOoF_O8VzrnF_pbNcz5w7xa72YJXvtNo2222AfUddm3ULs_fZX9O5iG9l9MD0JDWseR-EvJmeCCEmNT89We5-_UNzxc855T7T9uD5hyhM2_XijilWlBFC57XJZ8DPZHqJof__7zoE0xzvOPparZa8BpQLYmg6R47uRSB3Geb9bSGh4x7U6q0KBPw6HWt91kKVVKUhJJ0JsskYkn3zV3RcqBTKY5TF2KhzLhGTg7l5IKcnIrY2_U1s4YB5MLeuyTKdU9i7w4npvPvrjUGzogcjIKB9GmiKpFnkNpMVAjOrdXaDyL2iuTkyMbg6-EHaFIlcJDE1uV2jM2MJOq_iG31eqJtKPrNnSq51jYt3NlMitjzdTNdSfvtapiuqI9SCFyzxETsQaN56yFJLZVB8BOxtKeTvTH3W-rJj8BcnlkjRCIfXfxaz9j14fHo0B3uHx08ZjdEmDQyFtkW21zOV_AEYeDSPw1zj7Nvlz3Z_wFDim7o
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Urinary+galectin-3+binding+protein+as+a+biomarker+for+disease+activity+and+renal+pathology+characteristics+in+lupus+nephritis&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Ding%2C+Huihua&rft.au=Shen%2C+Yiwei&rft.au=Lin%2C+Cheng&rft.au=Qin%2C+Ling&rft.date=2022-03-28&rft.pub=BioMed+Central+Ltd&rft.issn=1478-6354&rft.volume=24&rft.issue=1&rft_id=info:doi/10.1186%2Fs13075-022-02763-4&rft.externalDocID=A698636778
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6362&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6362&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6362&client=summon